<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04403165</url>
  </required_header>
  <id_info>
    <org_study_id>20-00002</org_study_id>
    <secondary_id>1R21AG067549-01</secondary_id>
    <nct_id>NCT04403165</nct_id>
  </id_info>
  <brief_title>Locus-coeruleus Function in Normal Elderly and AD Risk</brief_title>
  <acronym>LEAD</acronym>
  <official_title>Locus-coeruleus Function in Normal Elderly and AD Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Growing evidence suggests that Alzheimer's disease (AD) pathological changes begin decades
      before clinical symptoms and tau abnormalities in the locus coeruleus (LC) can be observed
      since midlife. In previous research it has been demonstrated functional vulnerability of the
      LC to aging and stress, as well as an association between higher CSF tau and impaired sleep
      phenomena influenced by the LC. The study objective is to test whether LC dysfunction can be
      measured in preclinical AD stages by LC targeted imaging, and whether it objectively affects
      sleep architecture and attention; by asking 30 cognitively normal older adults to perform a
      full clinical evaluation, one night of polysomnography, a lumbar puncture (LP) to obtain
      cerebrospinal fluid, MRB PET-MR, as well as attention testing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is three-fold: to test whether lower NET availability in the LC is
      associated with: first, CSF tau levels typical of preclinical stages of AD (Aim 1); second,
      reduced REM and spindle density (Aim 2); and third, impaired performance on attention tasks
      (Aim 3). The goal is to test the overarching hypothesis that LC dysfunction occurs in
      preclinical AD stages, can be measured with MRB-PET, and translates into impairment of sleep
      architecture (LC tonic dysfunction) and attention (LC phasic dysfunction).
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in levels of Cerebrospinal fluid (CSF) tau correlation with Methylreboxetine (MRB) binding in the locus coeruleus (LC)</measure>
    <time_frame>visit 4 (1-4 weeks after the LP)</time_frame>
    <description>Early abnormal tau phosphorylation in locus coeruleus (LC) neurons may potentially lead to dysfunction of the LC. Studies characterizing the relationship between measures of LC function and Alzheimer's disease (AD) biomarkers are lacking. The levels of LC neuronal integrity by simultaneous PET-MR imaging using the norepinephrine transporter (NET)-selective radiotracer MRB will be assessed in 30 Cognitively Normal older adults.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the levels of norepinephrine transporter (NET) correlation with sleep</measure>
    <time_frame>Visit 3 (1-4 weeks after Visit 2)</time_frame>
    <description>Decreases in REM and spindle activity have been associated with cognitive impairment and risk for AD. LCs' dysfunction may have a contributive role of in AD progression, through its interference with normal sleep physiology. REM sleep and sleep spindles characteristics derived from in-lab will be measured in relation to LC dysfunction, sleep disturbances and AD progression.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in levels of norepinephrine transporter (NET) associated with decreased performance in attention test</measure>
    <time_frame>Visit 3 (1-4 weeks after Visit 2)</time_frame>
    <description>The psychomotor vigilance task (PVT) and the OddBall test, require the ability to keep task-focused attention, a process influenced by LC phasic activity. Decreased performance on attention tests may be a bystander of LC early dysfunction. Thus, we propose that decreased NET availability is associated with lower measures of task-attention performance (LC phasic dysfunction). This finding will support a link between impaired LC function and performance in attention tests.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in levels of norepinephrine transporter (NET) associated with decreased performance in attention test</measure>
    <time_frame>Visit 3 (1-4 weeks after Visit 2)</time_frame>
    <description>The OddBall test, require the ability to keep task-focused attention, a process influenced by LC phasic activity. Decreased performance on attention tests may be a bystander of LC early dysfunction. Thus, we propose that decreased NET availability is associated with lower measures of task-attention performance (LC phasic dysfunction). This finding will support a link between impaired LC function and performance in attention tests.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Locus-coeruleus functioning group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study will conduct brain scans of 30 people between the age of 60-75 as well as clinical and neuropsychological evaluations to test the locus-coeruleus (LC) functioning affects their sleep and thinking ability.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>nocturnal polysomnography (NPSG)</intervention_name>
    <description>The in-laboratory NPSG are those identical to the NPSG performed in clinical practice. The sleep study has no risks beyond the minor irritation that attachment of the recording electrodes on the skin occasionally may cause. The sleep study will be conducted for 1 night where REM sleep and sleep spindles characteristics will be measured.</description>
    <arm_group_label>Locus-coeruleus functioning group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lumbar Puncture (LP)</intervention_name>
    <description>Participants will undergo a fluoroscopy-guided lumbar puncture (LP) to obtain cerebrospinal fluid, the morning after the NPSG. The exposure risk of radiation exposure due to fluoroscopy is significantly outweighed by its benefits. Fluoroscopy uses X-rays for an exposure duration of approximately 5 seconds and it is a common radiological procedure. The estimate of the effective dose from the fluoroscopy study is about 1 mSv. At this radiation dose level there are no known risks, although there is always a slight risk of damage to cells or tissue from being exposed to any radiation, including the low levels of X-rays used for fluoroscopy-guided LP. These risk estimates are referenced by the FDA in association with the European Commission (Radiation Protection Report).</description>
    <arm_group_label>Locus-coeruleus functioning group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>MRB PET-MR scan</intervention_name>
    <description>[11C]MRB (MRB) PET imaging is performed under The Radioactive Drug Research Committee (RDRC) approval. PET/MR scans will be initiated immediately after intravenous injection of 15 mCi of high-specific activity MRB with simultaneous 90 minutes acquisition, routine MRI sequences for the structural and functional MR imaging will be performed using FDA approved coils. PET-MR scans will be performed on an integrated 3T PET-MR. MR and PET images will be evaluated by an experienced neuroradiologist and a routine clinical report will be done.</description>
    <arm_group_label>Locus-coeruleus functioning group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects with normal cognition and 60-75 years of age will be
             enrolled.

          -  Subjects will be within normal limits on neurological and psychiatric examinations.
             All subjects enrolled will have a CDR of 0.

          -  All subjects will have had a minimum of 12 years of education.

          -  An informed family member or life-partner (preferably bed-partner) will be interviewed
             over the phone or on the first or second visit to confirm the reliability of the
             subject interview.

        Exclusion Criteria:

          -  History of brain tumor, MRI evidence of brain damage or brain disease including
             significant trauma, hydrocephalus, seizures, stroke, mental retardation or other
             serious neurological disorder (e.g. Parkinson's disease or other movement disorders).

          -  Significant history of alcoholism or drug abuse.

          -  Significant history of psychiatric illness (e.g., schizophrenia, bipolar, PTSD, or
             life-long history of major depression).

          -  Geriatric Depression Scale (short form)&gt;6.

          -  Insulin dependent diabetes.

          -  Evidence of clinically relevant cardiac, pulmonary, endocrine or hematological
             conditions.

          -  Physical impairment of such severity as to adversely affect the validity of
             psychological testing.

          -  Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard
             for MRI imaging.

          -  History of a first-degree family member with early onset (age &lt;60 years) dementia.

          -  Irregular sleep-wake rhythms (based on the actigraphy recordings) or significant OSA
             (AHI4%â‰¥15).

          -  Taking Coumadin/warfarin and/or medications affecting cognition or sleep.

          -  Failure to complete all study visit within 4 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ricardo Osorio</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dishari Azad</last_name>
    <phone>646-754-2229</phone>
    <email>Dishari.azad@nyulangone.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ricardo Osorio</last_name>
    <phone>212-263-3255</phone>
    <email>ricardo.osorio@nyulangone.org</email>
  </overall_contact_backup>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 21, 2020</study_first_submitted>
  <study_first_submitted_qc>May 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 27, 2020</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All of the individual participant data collected during the trial, after deidentification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Immediately following publication. No end date.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the ricardo.osorio@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

